GENETIC EPIDEMIOLOGY OF ENVIRONMENTAL TOXICITY AND CANCER SUSCEPTIBILITY: HUMAN ALLELIC POLYMORPHISMS IN DRUG-METABOLIZING ENZYME GENES, THEIR FUNCTIONAL IMPORTANCE, AND NOMENCLATURE ISSUES

REFERENCES

• Meyer U. Genetic polymorphisms of drug metabolism. Fund. Clin. Pharmacol. 1990; 4: 595–615
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Idle J. R. Pharmacogenetic phenotyping and genotyping, present status and future potential. Clin. Pharmacokin. Concepts 1994; 26: 59–70
   PubMed Web of Science ®Google Scholar
• Kalow W., Bertilsson L. Interethnic factors affecting drug response. Adv. Drug Res. 1994; 23: 1–53
   Google Scholar
• Nebert D. W. Pharmacogenetics: 65 candles on the cake. Pharmacogenetics 1997; 7: 435–440
   Google Scholar
• Ambrosone C. B., Freudenheim J. L., Graham S., Marshall J. R., Vena J. E., Brasure J. R., Michalek A. M., Laughlin R., Nemoto T., Gillenwater K. A., Harrington A. M., Shields P. G. Cigarette smoking, N-acetyltransferase-2 genetic polymorphisms, and breast cancer risk. J. Am. Med. Assoc. 1996; 276: 1494–1501
   PubMed Web of Science ®Google Scholar
• Nebert D. W., McKinnon R. A., Puga A. Human drug-metabolizing enzyme polymorphisms: Effects on risk of toxicity and cancer. DNA Cell Biol. 1996; 15: 273–280
   PubMed Web of Science ®Google Scholar
• Nebert D. W. Growth signal pathways. Nature 1990; 347: 709–710
   PubMed Web of Science ®Google Scholar
• Nebert D. W. Proposed role of drug-metabolizing enzymes: Regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. Mol. Endocrinol. 1991; 5: 1203–1214
   PubMed Web of Science ®Google Scholar
• Nebert D. W. Drug-metabolizing enzymes in ligand-modulated transcription. Biochem. Pharmacol. 1994; 47: 25–37
   PubMed Web of Science ®Google Scholar
• Nebert D. W. Polymorphisms in drug-metabolizing enzymes: What is their clinical significance and why do they exist. Am. J. Hum. Genet. 1997; 60: 265–271
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Gonzalez F. J. P450 genes: Structure, evolution and regulation. Annu. Rev. Biochem. 1987; 56: 945–993
   PubMed Web of Science ®Google Scholar
• White J. A., McAlpine P. J., Antonarakis S., Cann H., Eppig J. T., Frazer K., Frezal J., Lancet D., Nahmias J., Pearson P., Peters J., Scott A., Scott H., Spurr N., Talbot C., Jr., Povey S. Guidelines for human gene nomenclature (1997). Genomics 1997; 45: 468–471
   PubMed Web of Science ®Google Scholar
• Antonarakis S. E. et al. (30 other coauthors), Recommendations for a nomenclature system for human gene mutations. Hum. Mutat. 1998; 11: 1–3
   PubMed Web of Science ®Google Scholar
• Schafer A. J., Hawkins J. R. DNA variation and the future of human genetics. Nature Biotechnol. 1998; 16: 33–39
   PubMed Web of Science ®Google Scholar
• Marez D., Legrand M., Sabbagh N., Guidice J. M. L., Spire C., Lafitte J. J., Meyer U. A., Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7: 193–202
   PubMedGoogle Scholar
• Hu Y., Oscarson M., Johansson I., Yue Q. Y., Dahl M. L., Tabone M., Arinco S., Albano E., Ingelman-Sundberg M. Genetic polymorphism of human CYP2E1: Characterization of two variant alleles. Mol. Pharmacol. 1997; 51: 370–376
   PubMed Web of Science ®Google Scholar
• Fairbrother K. S., Grove J., de Waziers I., Steimel D. T., Day C. P., Crespi C. L., Daly A. K. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998; 8: 543–552
   PubMedGoogle Scholar
• Cascorbi I., Brockmöller J., Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages, and the impact to lung cancer susceptibility. Cancer Res. 1996; 56: 4965–4969
   PubMed Web of Science ®Google Scholar
• Hildesheim A., Anderson L. M., Chen C. J., Cheng Y. J., Brinton L. A., Daly A. K., Reed C. D., Chen I. H., Caporaso N. E., Hsu M. M., Chen J. Y., Idle J. R., Hoover R. N., Yang C. S., Chhabra S. K. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J. Natl. Cancer Inst. 1997; 89: 1207–1212
   PubMed Web of Science ®Google Scholar
• Chang C. Y., Puga A. Constitutive activation of the aromatic hydrocarbon receptor. Mol. Cell Biol. 1998; 18: 525–535
   PubMed Web of Science ®Google Scholar
• Bale A. E., Nebert D. W., McBride O. W. Subchromosomal localization of the dioxin-inducible P1450 locus (CYP1) and description of two RFLPs detected with a 3′P1450 cDNA probe. Cytogenet. Cell Genet. 1987; 46: 574–575
   Google Scholar
• Hayashi S. I., Watanabe J., Nakachi K., Kawajiri K. Genetic linkage of lung cancer-associated Msp I polymorphisms with amino acid replacement in the heme-binding region of the human cytochrome P450IA1 gene. J. Biochem. (Tokyo) 1991; 110: 407–411
   PubMed Web of Science ®Google Scholar
• Wedlund P. J., Kimura S., Gonzalez F. J., Nebert D. W. I462V mutation in the human CYP1A1 gene: Lack of correlation with either the Msp I (M2) allele or CYP1A1 inducibility in a 3-generation family of East Mediterranean descent. Pharmacogenetics 1994; 4: 21–26
   PubMedGoogle Scholar
• Persson I., Johansson I., Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem. Biophys. Res. Commun. 1997; 231: 227–230
   PubMed Web of Science ®Google Scholar
• Crofts F., Cosma G. N., Currie D., Taioli E., Toniolo P., Garte S. J. A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis 1993; 14: 1729–1731
   PubMed Web of Science ®Google Scholar
• Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe I. Identification of genetically high risk individuals to lung cancer by polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 1990; 263: 131–133
   PubMed Web of Science ®Google Scholar
• Hayashi S., Watanabe J., Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and mu-class glutathione S-transferase genes. Jpn. J. Cancer Res. 1992; 83: 866–870
   PubMedGoogle Scholar
• Eaton D. L., Gallagher E. P., Bammler T. K., Kunze K. L. Role of cytochrome P450 1A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics 1995; 5: 259–274
   PubMedGoogle Scholar
• Aoyama T., Korzekwa K., Nagata K., Gillette J. R., Gelboin H. V., Gonzalez F. J. Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 1990; 126: 3101–3106
   PubMed Web of Science ®Google Scholar
• Sinclair P. R., Gorman N., Dalton T., Walton H. S., Bement W. J., Sinclair J. F., Smith A. G., Nebert D. W. Uroporphyria produced in mice by iron and 5-aminolevulinic acid does not occur in Cyp1a2(- / -) null mutant mice. Biochem. J. 1998; 330: 149–153
   PubMed Web of Science ®Google Scholar
• Shimada T., Yun C. H., Hiroshi Y., Gautier J. C., Beaune P. H., Guengerich F. P. Characterization of human lung microsomal cytochrome P4501A1 and its role in the oxidation of chemical carcinogens. Mol. Pharmacol. 1992; 41: 856–864
   PubMed Web of Science ®Google Scholar
• Swanson H. I., Bradfield C. A. The AH receptor: genetics, structure and function. Pharmacogenetics 1993; 3: 213–230
   PubMedGoogle Scholar
• Hahn M. E., Karchner S. I., Shapiro M. A., Perera S. A. Molecular evolution of two vertebrate aryl hydrocarbon (dioxin) receptors (AHR1 and AHR2) and the PAS family. Proc. Natl. Acad. Sci. USA 1998; 94: 13743–13748
   Web of Science ®Google Scholar
• Powell-Coffman J. A., Bradfield C. A., Wood W. B. Caenorhabditis elegans orthologs of the aryl hydrocarbon receptor and its heterodimerization partner the aryl hydrocarbon receptor nuclear translocator. Proc. Natl. Acad. Sci. USA 1998; 95: 2844–2849
   PubMed Web of Science ®Google Scholar
• Nebert D. W. The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects. CRC Crit. Rev. Toxicol. 1989; 20: 153–174
   Google Scholar
• Nebert D. W., Petersen D. D., Puga A. Human AH locus polymorphism and cancer: Inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1991; 1: 68–78
   PubMedGoogle Scholar
• Ema M., Ohe N., Suzuki M., Mimura J., Sogawa K., Ikawa S., Fujii-Kuriyama Y. Dioxin-binding activities of polymorphic forms of mouse and human aryl hydrocarbon receptors. J. Biol. Chem. 1994; 269: 27337–27343
   PubMed Web of Science ®Google Scholar
• Poland A., Palen D., Glover E. Analysis of the four alleles of the murine aryl hydrocarbon receptor. Mol. Pharmacol. 1994; 46: 915–921
   PubMed Web of Science ®Google Scholar
• Okey A. B., Manchester D. K., Feeley M. M., Grant D. L., Gilman A. Ah receptor characterization in human placenta samples. Organohalogen Compounds 1995; 25: 177–184
   Google Scholar
• Kawajiri K., Watanabe J., Eguchi H., Nakachi K., Kiyohara C., Hayashi S. Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics 1995; 5: 151–158
   PubMedGoogle Scholar
• Maier A., Micka J., Miller K., Denko T., Chang C. Y., Nebert D. W., Puga A. Aromatic hydrocarbon receptor (AHR) polymorphism: Development of new methods to correlate genotype with phenotype. Environ. Health Perspect. 1998; 106: 421–426
   PubMed Web of Science ®Google Scholar
• Fernandez-Salguero P., Hoffman S. M. G., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J. D., Evans W. E., Idle J. R., Gonzalez F. J. A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 1995; 57: 651–660
   PubMed Web of Science ®Google Scholar
• Ibeanu G. C., Blaisdell J., Ghanayem B. I., Beyeler C., Benhamou S., Bouchardy C., Wilkinson G. R., Dayer P., Daly A. K., Goldstein J. A. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8: 129–135
   PubMedGoogle Scholar
• Llerena A., Edman G., Cobaleda J., Benítez J., Schalling D., Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Acta Psychiatr. Scand. 1993; 87: 23–28
   PubMed Web of Science ®Google Scholar
• The Potential Role of the Cytochrome P-450 2D6 Pharmacokinetic Polymorphism in Drug Abuse, E. M. Sellers, S. V. Otton, R. F. Tyndale, R. S. Rapaka, N. Chiang, B. R. Martin. NIDA Research Monograph Series, Department of Health and Human Services, Rockville, MD 1997; 6–173
   Google Scholar
• Sachse C., Brockmöller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 1997; 60: 284–295
   PubMed Web of Science ®Google Scholar
• McLellan R. A., Oscarson M., Seidegård J., Evans D. A. P., Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7: 187–191
   PubMedGoogle Scholar
• Daly A. K., Brockmöller J., Broly F., Eichelbaum M., Evans W. E., Gonzalez F. J., Huang J. D., Idle J. R., Ingelman-Sundberg M., Ishizaki T., Jacqz-Aigrain E., Meyer U. A., Nebert D. W., Steen V. M., Wolf C. R., Zanger U. M. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193–201
   PubMedGoogle Scholar
• Vatsis K. P., Weber W. W., Bell D. A., Dupret J. M., Price-Evans D. A., Grant D. M., Hein D. W., Lin H. J., Meyer U. A., Relling M. V., Sim E., Suzuki T., Yamazoe Y. Nomenclature for NS-acetyltransferases. Pharmacogenetics 1995; 5: 1–17
   PubMedGoogle Scholar
• Doll M. A., Jiang W., Deitz A. C., Rustan T. D., Hein D. W. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem. Biophys. Res. Commun 1997; 233: 584–591
   PubMed Web of Science ®Google Scholar
• Hughes N. C., Janezic S. A., McQueen K. L., Jewett M. A. S., Castranio T., Bell D. A., Grant D. M. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998; 8: 55–66
   PubMedGoogle Scholar
• Butcher N. J., Ilett K. F., Minchin R. F. Functional polymorphism of the human arylamine Nx-acetyltransferase type I gene caused by C190T and G560A mutations. Pharmacogenetics 1998; 8: 67–72
   PubMedGoogle Scholar
• Otterness D., Szumlanski C., Lennard L., Klemetsdal B., Aarbakke J., Park-Hah J. O., Iven H., Schmiegelow K., Branum E., O'Brien J., Weinshilboum R. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin. Pharmacol. Ther. 1997; 62: 60–73
   PubMed Web of Science ®Google Scholar
• Mackenzie P. I., Owens I. S., Burchell B., Bock K. W., Bairoch A., Beélanger A., Fournel-Gigleux S., Green M., Hum D. W., Iyanagi T., Lancet D., Louisot P., Magdalou J., Chowdhury J. Roy, Ritter J. K., Schachter H., Tephly T. R., Tipton K. F., Nebert D. W. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255–269
   PubMedGoogle Scholar
• Monks T. J., Anders M. W., Dekant W., Stevens J. L., Lau S. S., van Bladeren P. J. Glutathione conjugate-mediated toxicities. Toxicol. Appl. Pharmacol. 1990; 106: 1–19
   PubMed Web of Science ®Google Scholar
• Seidegaård J., Pero R. W., Miller D. G., Beattie E. J. A glutathione transferase in human lymphocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 1986; 7: 751–753
   PubMed Web of Science ®Google Scholar
• Hallier E., Schröder K. R., Asmuth K., Dommermuth A., Aust B., Goergens H. W. Metabolism of dichloromethane (methylene chloride) to formaldehyde in human erythrocytes: Influence of glutathione transferase theta (GST T1-1). Arch. Toxicol. 1994; 68: 423–427
   PubMed Web of Science ®Google Scholar
• Haye J. D., Pulford D. J. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 1995; 30: 445–600
   PubMed Web of Science ®Google Scholar
• Watson M. A., Stewart R. K., Smith G. B., Massey T. E., Bell D. A. Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275–280
   PubMed Web of Science ®Google Scholar
• McLellan R. A., Oscarsson M., Alexandrie A. K., Seidegaård I., Evans D. A. P., Rannug A., Ingelman-Sundberg M. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. Mol. Pharmacol 1997; 52: 958–965
   PubMed Web of Science ®Google Scholar
• Henderson C. J., Smith A. G., Ure J., Brown K., Bacon E. J., Wolf C. R. Increased skin tumorigenesis in mice lacking π class glutathione S-transferases. Proc. Natl. Acad. Sci. USA 1998; 95: 5275–5280
   PubMed Web of Science ®Google Scholar
• Ross D. Quinone reductases. Comprehensive Toxicology, F. P. Guengerich. Elsevier Science, Oxford 1998; 3: 179–197
   Google Scholar
• Schulz W. A., Krummeck A., Rösinger I., Eickelmann P., Neuhaus C., Ebert T., Schmitz-Dräger B. J., Sies H. Increased frequency of a null-ellele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997; 7: 235–239
   PubMedGoogle Scholar
• Rothman N., Smith M. T., Hayes R. B., Traver R. D., Hoener B. A., Campleman S., Li G. L., Dosemeci M., Linet M., Zhang L., Xi L., Washolder S., Lu W., Meyer K. B., Titenko-Holland N., Stewart J. T., Yin S., Ross D. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C → T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997; 57: 2839–2842
   PubMed Web of Science ®Google Scholar
• Beetham J. K., Grant D., Arand M., Garbarino J., Kiyosue T., Pinto F., Oesch F., Belknap W. R., Shinozaki K., Hammock B. D. Gene evolution of epoxide hydrolases and recommended nomenclature. DNA Cell Biol. 1995; 14: 61–71
   PubMed Web of Science ®Google Scholar
• Hassett C., Aicher L., Sidhu J. S., Omiecinski C. J. Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants. Hum. Mol. Genet. 1994; 3: 421–428
   PubMed Web of Science ®Google Scholar
• Lancaster J. M., Brownlee H. A., Bell D. A., Futreal P. A., Marks J. R., Berchuck A., Wiseman R. W., Taylor J. A. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol. Carcinogen. 1996; 17: 160–162
   PubMed Web of Science ®Google Scholar
• McGlynn K. A., Rosvold E. A., Lustbader E. D., Hu Y., Clapper M. L., Zhou T., Wild C. P., Xia X. L., Baffoe-Bonnie A., Ofori-Adjei D., Chen G. C., London W. T., Shen F. M., Buetow K. H. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc. Natl. Acad. Sci. USA 1995; 92: 2384–2387
   PubMed Web of Science ®Google Scholar
• Gonzale F. J., Nebert D. W. Evolution of the P450 gene superfamily animal-plant “warfare,” molecular drive, and human genetic differences in drug oxidation. Trends Genet. 1990; 6: 182–186
   PubMed Web of Science ®Google Scholar
• De Laurenzi V., Rogers G. R., Hamrock D. J., Marekov L. N., Steinert P. M., Compton J. G., Markova N., Rizzo W. B. Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nature Genet. 1996; 12: 52–57
   PubMed Web of Science ®Google Scholar
• Stoilov I., Akarsu A. N., Sarfarazi M. Identification of three different truncating mutations in cytochrome P450 1B1 (CYP1B1) as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. 1997; 6: 641–647
   PubMed Web of Science ®Google Scholar
• de Vree J. M. L., Jacquemin E., Sturm E., Cresteil D., Bosma P. J., Aten J., Deleuze J. F., Desrochers M., Burdelski M., Bernard O., Elferink R. P. J. Oude, Hadchouel M. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl. Acad. Sci. USA 1998; 95: 282–287
   PubMed Web of Science ®Google Scholar
• Neber D. W., McKinnon R. A. Cytochrome P450: Evolution and functional diversity. Prog. Liv. Dis. 1994; 12: 63–97
   PubMedGoogle Scholar